Express Pharma

Teva Pharmaceuticals in partnership with IBM

1

To enable drug development and chronic disease management with Watson

IBM and Teva Pharmaceutical Industries announced a significant expansion of their existing global e-Health alliance with a focus on two key healthcare challenges: the discovery of new treatment options and improving chronic disease management. Both projects will run on the IBM Watson Health Cloud.

The expanded partnership features a new, three-year research collaboration to develop cognitive technologies that can enable a systematic approach to the emerging field of drug repurposing and deliver unprecedented scale in the discovery of new uses for existing drugs. The companies also announced that respiratory and central nervous system (CNS) diseases will be the first targets for their chronic disease management initiative, which will be the first project to integrate data from The Weather Company (an IBM Business) into the analysis. The joint work in chronic disease management emerges from Teva’s existing alliance with IBM as a Foundational Life Sciences Partner for the IBM Watson Health Cloud.

The announcements were made from the main stage at the World of Watson conference by Professor Yitzhak Peterburg, Teva’s Chairman of the Board of Directors, alongside Ginni Rometty, Chairman, President and CEO, IBM. Teva and IBM revealed, for the first time, that they are working together on an initiative that combines Teva’s therapeutic technologies with IBM Watson’s cognitive computing. Together, the companies aim to enable patients, healthcare providers, and payers to better understand and control chronic conditions, and track treatments.

The chronic disease management collaboration will combine cloud-connected drug delivery and app technology with more than six billion data points processed by Watson to provide actionable insights, including the first-ever integration of data from The Weather Company. Using Watson’s cognitive processing capabilities and newly developed algorithms these data may be used to calculate the prospective risk of health events, such as an asthma attack, with Teva delivering that information directly to caregivers and their patients via an app or other software interface.

The IBM Watson Health Cloud is a health-data enabled platform-as-a-service. It provides a foundation for cognitive offerings and is designed to help healthcare organisations derive individualised insights and obtain a more complete picture of the many factors that can affect people’s health. Teva’s use of the IBM Watson Health Cloud will comply with operational and security requirements for health data.

EP News Bureau

Comments are closed.